2. CONTENTS
1. Progestagen used during pregnancy
2. Absorption
3. Vaginal progestagen and 17 hp
4. Uses of progestagens in obstetrics
Conclusion
4AboubakrElnashar
3. I. Progestagen used during pregnancy
Progestogen
Compound with progesterone-like action
Produces progestational changes in an oestrogen-primed
endometrium.
Transform a proliferative into a secretory endometrium to
support pregnancy.
Natural
Synthetic.
AboubakrElnashar
4. Natural progestagens
Synthesized from: plant sources: soybeans and
Mexican yam roots
occasionally from: animal ovaries.
The hormone is not available from any natural source without extraction and
synthesis
Chemically and structurally identical to human
progesterone: “bioidentical” or “natural”.
Forms:
1. Oral
2. Intravaginal
3. Injectable
AboubakrElnashar
5. Synthetic Progestogens= Progestins
synthetically produced and differs in structure from
progesterone.
Progesterone derivatives:
17α-oH progesterone caproate
Stereoisomers of progesterone
Dydrogesterone
AboubakrElnashar
6. II. ABSORBTION
Transvaginal Progesterone.
:uterine effects with minimal systemic side effects
(Fanchin et al, 1997).
One hour after application Four hours after application
Endometrial Diffusion: Targeted delivery: Micronised Vaginal Progesterone
Progressive diffusion of progesterone from the cervix to the fundus of the uterus
(Bulletti et al. Hum Reprod. 1997)
AboubakrElnashar
10. Short cervix
Vaginal progesterone reduced the incidence of
PTL
(Fonseca et al, 2007; Hassan et al, 2011)
17a OH P C did not.
(Grobman et al, 2012)
Prior PTL
17a OH P C reduced the incidence of PTL
(Meis et al, 2003)
Vaginal progesterone did not.
(O’Brien et al, 2007)
AboubakrElnashar
11. IV. USES IN OBSTETRICS
1.Threatened miscarriages
2.Recurrent miscarriages
3.Prevention of PTL in singleton pregnancy
4.Prevention of PTL in twin pregnancy
AboubakrElnashar
12. 1. THREATENED MISCARRIAGES
Cochrane S R. 2011:
4 studies (421)
Pandian
2009
El-Zibdeh
2009
Palagiano
2004
Gerhard
1987
(n=191)(n=146)(n=50)(n=64)
initial 40 mg
oral
dydrogesterone
followed by 10
mg twice/d
continued until
16 w
90 mg
progesterone
(Crinone
8%) vaginal
sups once
daily
for 5d
oral
dydrogesterone
10 mg twice/d
continued for
1 w after
bleeding
stopped
25mg;
progesterone;
twice/d vaginal
sups
continued for
14 d after
bleeding stopped
AboubakrElnashar
13. Progestogens is effective in the tt of threatened
miscarriage
Reduced the risk of miscarriage by 47% (with a
confidence interval consistent with a risk reduction of 21% to 65%).
Significant reduction in the mean pain score
(Palagiano 2004)
Vaginal progesterone was not statistically effective
in reducing miscarriage
AboubakrElnashar
14. No statistically significant difference in between the women
who received
congenital abnormalities,
PIH
APH progestogens and those who did not.
Limitation of MA:
1. poor methodological quality of studies
2. small number of the participants
AboubakrElnashar
15. Carp, 2012, MA
11% absolute reduction in the miscarriage rate.
significant reduction of 47% in the odds for miscarriage
when dydrogesterone is compared to standard care
Many miscarriages are caused by genetic
abnormalities in the conceptus. It is unlikely that
progestins could prevent a miscarriage of this
etiology.
controlDydrogesterone
325335Patients
24%13%Miscarriage rate
AboubakrElnashar
16. Dante et al, 2013
No evidence to support the routine use of
progesterone vaginal supp for the treatment of
threatened miscarriage.
AboubakrElnashar
17. Yassaee et al, 2014
Rate of abortion was reduced in women treated
with 400 mg vaginal progesterone suppository
(Cyclogest) each day until their bleeding stopped in less
than one week.
However, the difference was not statistically
significant.
AboubakrElnashar
18. 2. RECURRENT MISCARRIAGES
Mechanism:
Immmunomodulatory actions
Decreasing proinflammatory
Increasing anti-inflammatory cytokines in early
pregnancy
[Choi et al, 2000].
Duration:
Start: 3 days after the LH surge {not to inhibit
ovulation}
Continue: until 10 w
{placental progesterone production fully functional}
AboubakrElnashar
19. Cochrane Database S R. 2013
4 trials, 225 women
El-Zibdeh
2005
Goldzieher 1964Le Vine
1964
Swyer
1953
1805456113
10 mg bid oral
Dydrogesterone,
5000 IU IM
hCG/4d
Duration: 12th w
10 mg/d oral
Dydrogesterone,
Duration: not
stated.
500 mg/w
IM
17 oh PC
Duration:
until 36 w
6 x 25 mg
progesterone
pellets
Duration: unclear.
AboubakrElnashar
20. 3 or more consecutive miscarriages
Progestogen tt:
significant decrease in miscarriage rate compared
to placebo or no tt
(Peto OR 0.39; 95% CI 0.21 to 0.72).
2 prior miscarriages.
a trend but not a significant reduction in miscarriage
rates
(Peto OR 0.68; 95% CI 0.43 to 1.07).
Limitations of MA:
these 4 trials were of poorer methodological quality.
AboubakrElnashar
21. Carp et al, 2015, SR and MA
509 women
13% absolute reduction in the miscarriage rate
significant reduction of 29% in the odds for miscarriage
when dydrogesterone is compared to
standard care
ControlDydrogesterone
23.5%10.5%Miscarriage rate
AboubakrElnashar
22. AboubakrElnashar
Coomarasamy et al, 2015: NEMJ
PROMISE STUDY: 836 patients
•multicenter, double-blind, placebo-controlled,
randomized trial
Vaginal suppositories: 400 mg micronized
progesterone in 1st T did not result in a significantly
higher LBR among women with a history of un RM.
23. 3. PREVENTION OF PTL IN SINGLETON
PREGNANCY
Mechanisms of action
1. Stimulate transcription of ZEB1 and ZEB2: inhibit connexin
43 (gap-junction protein that helps synchronize contractile
activity) and oxytocin-receptor gene
2. Decrease prostaglandin synthesis, infection-mediated
cytokine production (antiinflammatory effects) by fetal
membranes/placenta
3. Changes in PR-A and PR-B expression (decreased PR-
A/PR-B ratio keeps uterus quiescent)
4. Membrane-bound PR in myometrium
AboubakrElnashar
26. Cochrane Syst Rev.2013
Progesterone vs placebo for women with a
past history of PTB
statistically significant reduction in the risk of
Perinatal mortality
PTB less than 34 w
PTB less than 37 w
No differential effects in terms of:
Route of administration
time of commencing therapy
dose of progesterone
AboubakrElnashar
27. Progesterone vs placebo for women with a
short cervix identified on US
statistically significant reduction in the risk of
PTB less than 34 w
PTB at less than 28 w
It was not possible to assess the effect of
Route of administration
gestational age at commencing therapy, or
total cumulative dose of medication.
AboubakrElnashar
28. NICE, 2015
Offer prophylactic vaginal progesterone to women
with
no history of PTB or mid-trimester loss
in whom
TVS has been carried out between 16+0 and
24+0 w that reveals a cervical length of less than
25 mm.
AboubakrElnashar
29. Norman et al, 2016: Lancet.
OPPTIMUM study
1,228 women
Double blind, RCT, placebo trial
vaginal progesterone, 200 mg daily taken from 22-
24 to 34 w
women at risk of PTB
previous spontaneous birth at ≤34 w
cervical length ≤25 mm
Vaginal progesterone
not associated with reduced risk of PTB or
composite neonatal adverse outcomes
no longterm benefit or harm on outcomes in children at 2
y of age.
AboubakrElnashar
30. 4. PREVENTION OF PTL IN TWIN PREGNANCY
Maternal –Fetal medicine Society, 2012
No evidence of effectiveness
Cochrane Syst Rev.2013
Progesterone vs placebo for women with a
multiple pregnancy
no statistically significant differences
AboubakrElnashar
31. Schuit et al, 2014, MA
13 trials included 3768 women
Neither 17Pc (250 mg/w) nor
vaginal progesterone **
reduced the incidence of PTL
**Pessary: 200-400 mg
Gel: 90 mg
Sups: 100 -400 mg
Caps: 200 mg
AboubakrElnashar
32. In a subgroup of women with a cervical length of
≤25 mm:
vaginal progesterone reduced PTL when cervical
length was measured
at randomisation (15/56 vs 22/60; RR 0.57; 95% CI 0.47–0.70) or
before 24 w of gestation (14/52 vs 21/56; RR 0.56;95% CI
0.42–0.75).
AboubakrElnashar
33. Brubaker et al, 2015
vaginal progesterone therapy in twin pregnancies
with a CL ≤2.5 cm: an increased risk of PTB
Brizot et al, 2015
In nonselected twin pregnancies,
vaginal progesterone administration:
No prevent and does not reduce neonatal
morbidity and death.
AboubakrElnashar
34. CONCLUSION
1. T M and RM: Oral
2. PTL in Singleton:
Short cx: vaginal (NICE, 2015)
Previous PTL: IM
4. PTL in Twin:
Short cx: vaginal (Schuit et al, 2014, MA)
AboubakrElnashar
35. 263 lectures
1. My scientific
page on face
book: 3604
members
2. Slide share: 1228
followers
Aboubakr Elnashar